We are live on ! Find out more
PYXS icon

Pyxis Oncology

99 hedge funds and large institutions have $49.2M invested in Pyxis Oncology in 2024 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 33 increasing their positions, 19 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,884% more call options, than puts

Call options by funds: $1.59M | Put options by funds: $80K

100% more funds holding in top 10

Funds holding in top 10: 24 (+2)

74% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 19

39% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 18

8% more funds holding

Funds holding: 9299 (+7)

6.13% more ownership

Funds ownership: 46.93%53.06% (+6.1%)

52% less capital invested

Capital invested by funds: $102M → $49.2M (-$53.1M)

Holders
99
Holders Change
+7
Holders Change %
+7.61%
% of All Funds
1.3%
Holding in Top 10
4
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+100%
% of All Funds
0.05%
New
25
Increased
33
Reduced
19
Closed
18
Calls
$1.59M
Puts
$80K
Net Calls
+$1.51M
Net Calls Change
-$238K
Name Holding Trade Value Shares
Change
Change in
Stake
Ohio Public Employees Retirement System (OPERS)
51
Ohio Public Employees Retirement System (OPERS)
Ohio
$45.4K
Wells Fargo
52
Wells Fargo
California
$45.2K +$13.6K +4,724 +20%
Royal Bank of Canada
53
Royal Bank of Canada
Ontario, Canada
$44K -$22.1K -7,673 -22%
Mirae Asset Global ETFs Holdings
54
Mirae Asset Global ETFs Holdings
Hong Kong
$43.7K +$3.51K +1,216 +5%
JP Morgan Chase
55
JP Morgan Chase
New York
$42.2K +$14.7K +5,099 +23%
Cetera Investment Advisers
56
Cetera Investment Advisers
Illinois
$41.9K +$2.88K +1,000 +4%
Commonwealth Equity Services
57
Commonwealth Equity Services
Massachusetts
$41K +$28.8K +10,000 +62%
Invesco
58
Invesco
Georgia
$39.6K +$12.1K +4,191 +20%
Qube Research & Technologies (QRT)
59
Qube Research & Technologies (QRT)
United Kingdom
$38.3K -$139K -48,363 -66%
CF
60
Corebridge Financial
Texas
$37.9K -$5.29K -1,833 -7%
LPL Financial
61
LPL Financial
California
$35.3K +$22.5K +7,800 +53%
XT
62
XTX Topco
Cayman Islands
$35.1K -$180K -62,279 -73%
IIM
63
INTECH Investment Management
Florida
$35.1K +$21.9K +7,594 +51%
Osaic Holdings
64
Osaic Holdings
Arizona
$34.9K +$47.8K +16,558 +284%
CM
65
Caption Management
Oklahoma
$34.8K +$64.3K +22,306 New
Ameriprise
66
Ameriprise
Minnesota
$34.7K +$64.2K +22,251 New
Two Sigma Investments
67
Two Sigma Investments
New York
$26.6K -$21.7K -7,515 -31%
ProShare Advisors
68
ProShare Advisors
Maryland
$25.8K +$47.8K +16,568 New
T. Rowe Price Associates
69
T. Rowe Price Associates
Maryland
$25K
VOYA Investment Management
70
VOYA Investment Management
Georgia
$24.8K -$3.75K -1,302 -8%
OAM
71
Oxford Asset Management
United Kingdom
$22.5K +$41.6K +14,438 New
AllianceBernstein
72
AllianceBernstein
Tennessee
$21K
Mariner
73
Mariner
Kansas
$20.1K +$37.1K +12,863 New
CUAMC
74
China Universal Asset Management Company
China
$19.7K +$36.4K +12,609 New
ACM
75
ADAR1 Capital Management
Texas
$15.6K

PYXS Hedge Fund Activity: Q4 2024 in Review

99 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Pyxis Oncology (PYXS) for Q4 2024, worth a combined $49.2M — down 52% from $102M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new PYXS positions and 18 closed out — a net gain of 7 holders — while 33 added to existing stakes and 19 trimmed.

The largest buyer was Millennium Management, adding an estimated $3.1M. The largest seller was Deep Track Capital, exiting entirely with an estimated $15.4M sold.

  • 99 institutional investors held Pyxis Oncology (PYXS) as of Q4 2024, up from 92 in Q3 2024.
  • Funds reported $49.2M of Pyxis Oncology stock for Q4 2024, down 52% quarter-over-quarter.
  • 25 funds opened new Pyxis Oncology positions in Q4 2024 and 18 closed out, a net change of +7 holders.
  • The largest Pyxis Oncology buyer in Q4 2024 was Millennium Management, an estimated $3.1M added.
  • The largest Pyxis Oncology seller in Q4 2024 was Deep Track Capital, an estimated $15.4M sold.

Based on aggregated 13F filings for Q4 2024.